openPR Logo
Press release

Global Biosimilar Insulin Market Opportunity and Clinical Insight Outlook 2022 Report

05-07-2018 06:10 AM CET | Health & Medicine

Press release from: Kuick Resarch

Global Biosimilar Insulin Market Opportunity and Clinical

“Global Biosimilar Insulin Market Opportunity and Clinical Insight Outlook 2022” report gives comprehensive insight on clinical and non-clinical issues involved with growth of global biosimilar insulin market. This report analyzes various aspects like rationale design of insulin molecule, mechanism of insulin in diabetes, engineering of synthetic insulin, global aspects of biosimilar insulins along with market overview, biosimilar insulin clinical pipeline insight and future trends for the development of biosimilar insulin market.

Download Report Sample Weblink:

https://www.kuickresearch.com/report-global-biosimilar-insulin-market-opportunity-and-clinical-insight-outlook-2022.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

Prologue to Insulin Biosimilars
1.1 Outline Towards Insulin
1.2 Trail of Insulin Evolution and Development

Rationale Design of Insulin Molecule
2.1 Structure of Insulin Polypeptide
2.2 Biosynthesis of Insulin
2.3 Secretion of Insulin

Mechanism of Insulin in Diabetics
3.1 Glucose Metabolism of Insulin
3.2 Impact of Insulin Dysregulation in Diabetes 1
3.3 Impact of Insulin Resistance in Diabetes 2

Engineering of Synthetic Insulin
4.1 Production of Human Insulin
4.2 Categorization of Insulin and Its Analogues
4.2.1 Rapid Acting Insulins
4.2.2 Short Acting Insulins
4.2.3 Intermediate Insulin
4.2.4 Long Lasting Insulins

Insulinotherapeutics in Diabetes
5.1 Conventional Insulinotherapy
5.2 Flexible or Intensive Insulinotherapy

Global Economic Aspects of Insulin
6.1 Skyrocketing Cost of Insulin Therapies
6.2 Emergence of Biosimilar

Global Economic Cost of Diabetes
7.1 Monetary Burden of Diabetes
7.2 US
7.3 Europe
7.4 Japan
7.5 China
7.6 India

Global Aspects of Biosimilar Insulins
8.1 US
8.2 Europe
8.3 Japan
8.4 Asia (Excluding Japan)

Global Biosimilar Insulin Market Overview
9.1 Preface to Biosimilar Insulin Market
9.2 Biosimilar Competition Assessment

Global Biosimilar Insulin Clinical Pipeline Insight

Marketed Biosimilar Insulin Clinical Insight by Company, Indication and Phase
11.1 Insulin Biosimilar (Wosulin-R)
11.2 Insulin Glargine Biosimilar (Glaritus, Glaritus Cart, Glaritus DispoPen)
11.3 Insulin Glargine Biosimilar (Abasaglar, Abasria and Basalgar)
11.4 Insulin Suspension Isophane/Insulin Biosimilar (Jusline 30/70)
11.5 Insulin Glargine Biosimilar (Basalog and GALACTUS)
11.6 Insulin Suspension Isophane Biosimilar (Jusline N)
11.7 Insulin Suspension Isophane/Insulin Biosimilar (Insulin H Mix)
11.8 Insulin Suspension Isophane Biosimilar (Insulin Hbio NPH)
11.9 Insulin Biosimilar (Insulin Hbio R)
11.10 Insulin Glargine Biosimilar (Basalin)
11.11 Insulin/Insulin Suspension Isophane Biosimilar (Wosulin 30/70, 50/50)
11.12 Insulin Suspension Isophane Biosimilar (Wosulin-N)
11.13 Insulin Biosimilar (Jusline R)
11.14 Insulin Glargine Biosimilar (Basugine)
11.15 Insulin Biosimilar (Insugen)

Biosimilar Insulin Future Targeted Market
12.1 Global High Prevalence of Diabetics
12.2 Global Prevalence of Obesity

Global Biosimilar Insulin Market Dynamics
13.1 Accelerating Parameters
13.2 Major Challenges of Biosimilar Insulin Market

Future Implications of Biosimilar Insulin

Competitive Landscape
15.1 Biocon
15.2 Biogenomics
15.3 Eli Lilly
15.4 GanandLee Pharmaceuticals
15.5 Geropharm
15.6 Julphar Gulf Pharmaceutical Industries
15.7 Paras Biopharmaceuticals
15.8 Samsung Bioepis
15.9 Sedico
15.10 Wockhardt

Figure 1-1: Major Historical Events in Discovering Insulin
Figure 2-1: Primary Structure of Insulin with Polypeptidic Chains
Figure 2-2: Illustration of Biosynthesis from Preproinsulin to Proinsulin
Figure 2-3: Mechanism of Insulin Release from the Pancreas
Figure 3-1: Mechanism of glucose Uptake by Insulin Molecule
Figure 3-2: Deficiency of Insulin Leading towards the Type I Diabetes
Figure 3-3: Insulin resistance Shown by the Type 2 Diabetes
Figure 4-1: Process of Generating Recombinant Insulin in Bacterial Cell
Figure 4-2: Different Types of Insulin and Their Brand Names with Time of Action
Figure 5-1: Relationships among Components of Insulin, Injection Times and Blood Glucose Testing
Figure 5-2: Insulin Release during Conventional Insulinotherapy
Figure 5-3: Insulin release at Intensified or Flexible Insulinotherapy
Figure 6-1: Representation of Rising Cost of Insulin per Unit
Figure 7-1: Illustration of the Total Cost Distribution of Diabetes
Figure 7-2: Global Estimated Total Expenditure of Diabetes (US$ Billion), 2015 and 2040
Figure 7-3: Top 10 Countries by Highest Spending Per Patient with Diabetes (US$)
Figure 7-4: Top 10 Countries by Lowest Spending Per Patient with Diabetes (US$)
Figure 7-5: US - Estimated Total Cost of Diabetes and Obesity (US$ Billion)
Figure 7-6: Representation of Cost of Insulin among Different Countries, 2016
Figure 7-7: Projected Cost of Diabetes in Europe
Figure 7-8: Estimated Prevalence of Diabetes in Japan (In Million)
Figure 7-9: Projected Number of Diabetic Cases in China (Million)
Figure 7-10: India - Increasing Prevalence of Diabetes and Future Projections (Million)
Figure 8-1: Demonstration Comparative Price of Lantus Insulin in US and Other Countries
Figure 8-2: Highest Growth in Number of Biosimilars Candidates in South East Asian Region
Figure 9-1: Cost savings with Biosimilars and Generics as Compared to the Branded Versions
Figure 9-2: Global Insulin Market Assessment (US$ Billion), 2016-2022
Figure 9-3: Global Market Shares of Three Leading Companies in the Insulin Market
Figure 9-4: Illustrations of Lantus (Insulin Glargine) Revenues by Sanofi’s (Billion Euros)
Figure 9-5: Market Revenues of Novo Nordisk in Modern Insulin Market (DKK Billion)
Figure 10-1: Number of Biosimilar Insulin in Clinical Pipeline, 2017-2022
Figure 10-2: Biosimilar Insulin in Clinical Pipeline (%), 2017-2022
Figure 12-1: Top 5 Countries with High Diabetes Prevalence in Adults by 2030(in Millions)
Figure 12-2: Top 10 Countries by Highest Prevalence of Diabetes (%)
Figure 12-3: Global Increasing Prevalence of Diabetes Prevalence (In Millions)
Figure 12-4: Estimated Prevalence of Obesity among Various Countries (2025)
Figure 12-5: Increasing Relative Risk of Diabetes with Increasing BMI
Figure 13-1: Trends of High Cost of Insulin from 2010 till 2015 in US
Figure 13-2: The Major Favorable Parameters for Growth of Biosimilar Insulin Market
Figure 13-3: Major Barriers Encountered by the Insulin Biosimilar Market

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Biosimilar Insulin Market Opportunity and Clinical Insight Outlook 2022 Report here

News-ID: 1040667 • Views: 247

More Releases from Kuick Resarch

Global Cell Therapy Market To Surpass US$ 35 Billion By 2026
Global cell therapy market is expected to surpass US$ 35 Billion by 2026 as per recent report “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” published by Kuick Research. Increasing investment, gaining research and development activities along with new technological advancement will drive the global cell therapy market. Download Report: https://www.kuickresearch.com/report-global-cell-therapy-market,-clinical-trials,-therapy-price-and-opportunity-insight-2026.php “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” Report Highlights: • Global Cell Therapy
Cell Therapy Market Size Growth Cell Therapy Clinical Trials Market Forecast 202 …
Cell therapies are still in the infancy stages of the clinical development and are expected to evolve in the market with a vast number of opportunities in the healthcare industry. In order to form a stable base for process evaluation and development it will be essential to understand the quality of cell based products. With an increasing number of cell therapies and clinical indications being assessed, it is clear that
Global Cell Therapy Market Size Analysis Clinical Trials Growth Forecast 2026
"Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights: • Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 • Cell Therapy Clinical Trial Insight by Indication, Company & Country • Global Cell Therapy Clinical Pipeline: 767 Cell Therapies • Globally Marketed Cell Therapies: 25 Cell Therapies • Maximum Number of Marketed Cell Therapies In USA: 15 Therapies • Price & Product Insight By Region/Country • Regional Analysis of the Cell Therapy Market Download
CAR T Cell Therapy Changing The Cancer Oncology Drug Market Landscape
" Global CAR T Cell Therapy Market & Clinical Trials Insight 2024" Report Highlights: • CAR T-Cell Therapies Delivery Pipeline & Mechanism of Action • Sales Analysis of CAR - T Cell Therapy • CAR - T Cell Therapy Market Opportunity: US$ 700 Million • CAR-T Cell Therapies Clinical Pipeline by Company, Indication & Phase: 236 Therapies • CAR-T Cell Therapies in Highest Phase: Preclinical • Marketed CAR-T Cell Therapies: 2 ( Yescarta & Kymriah) • Global Market Scenario of

All 5 Releases


More Releases for Insulin

Insulin Patch Pumps Market Report 2018: Segmentation by Insulin Type (Bolus Insu …
Global Insulin Patch Pumps market research report provides company profile for Roche Holding AG, Cellnovo Group SA, Spring Health Solution Ltd., Debiotech, CeQur SA, Valeritas, Becton Dickenson & Company, Insulet Corporation, Johnson & Johnson, Medtrum Technologies Inc. and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue,
Insulin Delivery Devices Market - Insights
Insulin is vital for people suffering from type 1 diabetes and type 2 diabetes. In the past, patients with diabetes had to inject insulin using large glass syringes and reusable needles, both of which needed sterilization by boiling after each use. Improvements and innovations has led to development of insulin delivery devices such as pens and insulin pumps. Furthermore, insulin analogs have become available that enable both continuous subcutaneous insulin
Biosimilar Insulin Market Access
Boston, MA ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer
Biosimilar Insulin Market Access
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants
Biosimilar Insulin Market Biosimilar Insulin Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Prologue to Insulin Biosimilars 1.1 Outline Towards Insulin 1.2 Trail of Insulin Evolution and Development Rationale Design of Insulin Molecule 2.1 Structure of Insulin Polypeptide 2.2 Biosynthesis of Insulin 2.3 Secretion of Insulin Mechanism of Insulin in Diabetics 3.1 Glucose Metabolism of Insulin 3.2 Impact of Insulin Dysregulation in Diabetes 1 3.3 Impact
Global Insulin Delivery Machine Market: By Types - Insulin Pens, Insulin Pumps, …
Latest industry research report on: Global Insulin Delivery Machine Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts Request For Sample Report @https://www.marketresearchreports.biz/sample/sample/1181480 This report studies Insulin Delivery Machine in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in